PebbleAtlas
PEBBLE / ATLAS
Open research access
PRECLINICAL PUBLICATION · 2018

Bone marrow-derived mononuclear cell therapy can attenuate systemic inflammation in rat heatstroke.

Rat / Other

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

PMID 30445981 ↗2018Reported benefit

Bone marrow-derived mononuclear cell therapy can attenuate systemic inflammation in rat heatstroke.

RatOtherWistar (specific pathogen free); donor cells also from GFP transgenic Wistar ratsMalen = Survival study 36 rats (n=12 each in control and heat stres…Intravenous5.0 x 10^6 viable bone marrow-derived mononuclear cells in…Immediately after heat stress

Model: Non-exertional heatstroke under medetomidine 0.375 mg per kg, midazolam 2.0 mg per kg and butorphanol 2.5 mg per kg subcutaneously; rectal temperature raised approximately 1.0 degree Celsius every 5 minutes and held at 41.8 plus or minus 0.2 degrees Celsius for 30 minutes, then recovery at 24 degrees Celsius with 35 mL per kg subcutaneous saline to prevent dehydration

Bone marrow-derived mononuclear cells raised 7 day survival from 41.7 percent to 83.3 percent (p=0.021), lowered serum tumour necrosis factor alpha, histone H3 and syndecan-1, and reduced alveolar oedema and glycocalyx loss, although interleukin-6 and interleukin-1 beta reductions were not signific…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.